J&J grants Ascletis Chinese rights to HIV candidate

The Janssen R&D Ireland unit of Johnson & Johnson (NYSE:JNJ) granted Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) exclusive, Chinese rights to develop and commercialize Janssen's HIV compound TMC310911. J&J is eligible for undisclosed royalties based on Chinese sales of the HIV protease inhibitor, which has completed a Phase IIa trial in treatment-naïve HIV patients. Ascletis and J&J declined to disclose details. ...